Cytokine Release Syndrome: all 163 studies

Page 1 of 2. Open to participants first (31), then studies with results posted, then the rest; newest registration first within each.

• Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell TherapyNot yet recruitingNCT07911540Not applicable
• CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid LeukemiaNot yet recruitingNCT07897136Phase 1
• RPM Signals in Outpatient CAR T TherapyNot yet recruitingNCT07882732
• CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07841002Phase 1
• INfections in Patients Treated With CAR-TNot yet recruitingNCT07713511
• Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingNCT07657312Phase 2
• Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)RecruitingNCT07609940Phase 4
• NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)RecruitingNCT07502118Phase 2/3
• Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse EventEnrolling by invitationNCT07499128Not applicable
• Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic LymphohistiocytosisNot yet recruitingNCT07497438Phase 3
• Jafron Cytokine Adsorber During Pediatric Open-Heart SurgeriesNot yet recruitingNCT07393087Not applicable
• Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell ImmunotherapyRecruitingNCT07390071Not applicable
• Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I StudyRecruitingNCT07169487Phase 1
• Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)Not yet recruitingNCT07166549Phase 1
• A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaRecruitingNCT07106671Phase 2
• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingNCT06806033Phase 2
• Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)RecruitingNCT06684379Phase 1/2
• Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial SepsisRecruitingNCT06491966
• Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to EpcoritamabRecruitingNCT06447376Phase 1
• Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple MyelomaRecruitingNCT06421675Phase 2
• Early Detection of Complications During Immunotherapy for Haematological MalignancyRecruitingNCT06377059Not applicable
• Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE StudyRecruitingNCT06339177
• MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS PatientsNot yet recruitingNCT06308926Phase 2
• EFFECTS OF EXTRACORPOREAL CYTOKINE ELIMINATION ON HEMODYNAMIA AND MORTALITY IN CRITICAL PATIENTSEnrolling by invitationNCT05984407
• Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingNCT05972135Phase 2
• Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell TherapyRecruitingNCT05905328Phase 1/2
• Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic LymphohistiocytosisRecruitingNCT05491304Phase 4
• Multiparametric Cardiac MRI in Patients Under CAR T-cell TherapyRecruitingNCT05414162
• Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like SyndromeRecruitingNCT05306080Early Phase 1
• Immune Modulation by Exosomes in COVID-19RecruitingNCT05191381
• CytOSorb TreatMent Of Critically Ill PatientS RegistryRecruitingNCT05146336
• Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell TherapyCompletedNCT04975555Phase 2Results posted
• Efficacy and Safety of Itolizumab in COVID-19 ComplicationsCompletedNCT04475588Phase 2Results posted
• Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)CompletedNCT04466098Phase 2Results posted
• A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19TerminatedNCT04415073Phase 2Results posted
• Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)TerminatedNCT04377620Phase 3Results posted
• Fluoxetine to Reduce Intubation and Death After COVID19 InfectionCompletedNCT04377308Phase 4Results posted
• Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSCompletedNCT04374149Phase 2Results posted
• INB03 for the Treatment of Pulmonary Complications From COVID-19TerminatedNCT04370236Phase 2/3Results posted
• Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19TerminatedNCT04365985Phase 2Results posted
• Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)TerminatedNCT04365257Phase 2Results posted
• Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced PneumoniaCompletedNCT04362813Phase 3Results posted
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine StormCompletedNCT04362137Phase 3Results posted
• Early Treatment of Cytokine Storm Syndrome in Covid-19CompletedNCT04362111Phase 3Results posted
• Rhu-pGSN for Severe Covid-19 PneumoniaCompletedNCT04358406Phase 2Results posted
• Etoposide in Patients With COVID-19 InfectionTerminatedNCT04356690Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)CompletedNCT04351243Phase 2Results posted
• A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated NeurotoxicityCompletedNCT04150913Phase 2Results posted
• A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyCompletedNCT04071366Phase 2Results posted
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingNCT03696784Phase 1Results posted
• A Phase I Trial of Anti-GD2 T-cells (1RG-CART)CompletedNCT02761915Phase 1Results posted
• Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus PatientsCompletedNCT02000817Phase 1/2Results posted
• Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung CancerActive, not recruitingNCT07885332
• Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With TebentafuspWithdrawnNCT07803562Phase 2
• Pre-emptive Anakinra for Cytokine Event ReductionWithdrawnNCT06703216Phase 1/2
• Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19CompletedNCT06676709Phase 1/2
• Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient OutcomesCompletedNCT06390748Phase 2
• Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMMWithdrawnNCT06352866Phase 2
• Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).CompletedNCT06279910
• Interleukin-34 in Stage I and II PeriodontitisCompletedNCT06052774Not applicable
• Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart FailureCompletedNCT06003972Phase 2
• 101-PGC-005 for the Treatment of COVID-19Active, not recruitingNCT05656521Phase 2
• Anakinra in Dengue With Hyperinflammation ( AnaDen )Active, not recruitingNCT05611710Phase 2
• Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity SyndromeCompletedNCT05510596Not applicable
• Relationship Between Oral Findings and Salivary Factors in Sars-Cov-2 PatientsCompletedNCT05476848Not applicable
• Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 PatientsCompletedNCT05445089Phase 2/3
• Intercellular Adhesion Molecule-1 and TNF-α in Patients With COVID-19CompletedNCT05408325
• Jafron Haemoadsorption During Cardiopulmonary BypassCompletedNCT05349669Phase 2
• Immune Response Following COVID-19 in Hemodialysis PatientsCompletedNCT05307601
• Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 PatientsStatus unknownNCT05216562Phase 2/3
• A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of CareTerminatedNCT05195749Phase 2
• Plasma Exchange in Covid-19 Patients With Anti-interferon AutoantibodiesStatus unknownNCT05182515Phase 3
• CLinical Efficacy of Hemoperfusion With a Cytokine Adsorber in Norepinephrine-Resistant SEptic ShockStatus unknownNCT05136183Not applicable
• High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19WithdrawnNCT05133635Phase 4
• PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19Status unknownNCT05096052Phase 3
• Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effects on Covid-19 Infected Infants and SeverityStatus unknownNCT05071690
• Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDSStatus unknownNCT05058742Not applicable
• Menstrual Blood Stem Cells in Severe Covid-19CompletedNCT05019287Phase 1/2
• Tazemetostat for the Treatment of Moderate to Severe COVID-19 InfectionWithdrawnNCT05018975Phase 2
• Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult PatientsStatus unknownNCT05013034Phase 2
• Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University HospitalCompletedNCT04979884Phase 3
• Prospective Study for the Application of Cytosorb® in Critically Ill PatientsCompletedNCT04913298Not applicable
• Cytokine Adsorption in Severe, Refractory Septic ShockCompletedNCT04910893Not applicable
• Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot StudyStatus unknownNCT04904783Not applicable
• Cytokine Hemoadsorption in ECMO PatientsCompletedNCT04901338
• Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 PneumoniaCompletedNCT04873141
• Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.Status unknownNCT04869579Phase 2
• UNITE Study (UMN-SW) for COVID-19CompletedNCT04854798Not applicable
• Inflammatory Response to Opioid Versus Opioid Free AnesthesiaCompletedNCT04854252Not applicable
• Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19WithdrawnNCT04828538Not applicable
• Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 VaccineCompletedNCT04798677Not applicable
• Cyclosporine on Day Zero as Prophylaxis for Cytokine Release SyndromeStatus unknownNCT04781803Phase 2
• Paediatric Inflammatory Multisystem Syndrome During COVID-19 PandemicCompletedNCT04761913
• Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in IndonesiaStatus unknownNCT04753476Phase 2
• Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 InfectionsCompletedNCT04751643Not applicable
• Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) InfectionCompletedNCT04739345Not applicable
• Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian PatientsCompletedNCT04738760
• Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm SyndromeCompletedNCT04734678
• Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)CompletedNCT04724629Phase 3
• Safety and Tolerability Study of IV ST266 in COVID-19 SubjectsCompletedNCT04720378Phase 1

← Cytokine Release Syndrome overview